miR‑339‑5p inhibits cell migration and invasion in vitro and may be associated with the tumor‑node‑metastasis staging and lymph node metastasis of non‑small cell lung cancer

Li,Yun; Zhao,Weiguo; Bao,Pengtao; Li,Chunsun; Ma,Xiu  Qing; Li,Yanqing; Chen,Liang  An

doi:10.3892/ol.2014.2165

miR‑339‑5p inhibits cell migration and invasion in vitro and may be associated with the tumor‑node‑metastasis staging and lymph node metastasis of non‑small cell lung cancer

Authors:
- Yun Li
- Weiguo Zhao
- Pengtao Bao
- Chunsun Li
- Xiu Qing Ma
- Yanqing Li
- Liang An Chen
View Affiliations

Affiliations: Department of Respiratory Medicine, Chinese PLA General Hospital and Chinese PLA Medical School, Beijing 100853, P.R. China, Department of Respiratory Medicine, The 309th Hospital of Chinese People's Liberation Army, Beijing 100091, P.R. China
Published online on: May 22, 2014 https://doi.org/10.3892/ol.2014.2165
Pages: 719-725

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the potential role of microRNA (miRNA or miR) in invasion and metastasis of non‑small cell lung cancer (NSCLC). miRNA‑microarray analysis was used to detect the differentially expressed miRNAs between various metastatic levels of NSCLC cells. The microarray results were verified by quantitative polymerase chain reaction. The most clearly altered miRNA, miR‑339‑5p, was transfected into NSCLC cells and cell migration and invasion were investigated. The expression of miR‑339‑5p was 3.4662‑fold higher in the lower metastatic NSCLC cells. miR‑339‑5p significantly decreased tumor‑cell migration and the invasion capacity in vitro. In conclusion, miR‑339‑5p is important in NSCLC invasion and metastasis, indicating that miR‑339‑5p could be further evaluated as a biomarker for predicting the survival time of patients with NSCLC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012.
2	Lee Y, Ahn C, Han J, et al: The nuclear RNase III Drosha initiates microRNA processing. Nature. 425:415–419. 2003.
3	Lund E, Güttinger S, Calado A, et al: Nuclear export of microRNA precursors. Science. 303:95–98. 2004.
4	Lee Y, Jeon K, Lee JT, et al: MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 21:4663–4670. 2002.
5	Rana TM: Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol. 8:23–36. 2007.
6	Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006.
7	Gibbons DL, Lin W, Creighton CJ, et al: Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 23:2140–2151. 2009.
8	Ceppi P, Mudduluru G, Kumarswamy R, et al: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res. 8:1207–1216. 2010.
9	Sobin LH, Gospodarowicz MK and Wittekind CH; International Union Against Cancer. TNM Classification of Malignant Tumours. 7th edition. WileyBlackwell; New York, NY: 2010
10	Wu ZS, Wu Q, Wang CQ, et al: MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis. BMC Cancer. 10:5422010.
11	Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 449:682–688. 2007.
12	Frankel LB, Christoffersen NR, Jacobsen A, et al: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 283:1026–1033. 2008.
13	Edmonds MD, Hurst DR, Vaidya KS, et al: Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J Cancer. 125:1778–1785. 2009.
14	Dews M, Homayouni A, Yu D, et al: Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 38:1060–1065. 2006.
15	Foekens JA, Sieuwerts AM, Smid M, et al: Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA. 105:13021–13026. 2008.
16	Song G, Zhang Y and Wang L: MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem. 284:31921–31927. 2009.
17	Yu F, Yao H, Zhu P, et al: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 131:1109–1123. 2007.
18	Xiao F, Zuo Z, Cai G, et al: miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 37(Database issue): D105–D110. 2009.
19	Krek A, Grün D, Poy MN, et al: Combinatorial microRNA target predictions. Nat Genet. 37:495–500. 2005.
20	John B, Enright AJ, Aravin A, et al: Human microRNA targets. PLoS Biol. 2:e3632004.
21	Lewis BP, Shih IH, Jones-Rhoades MW, et al: Prediction of mammalian microRNA targets. Cell. 115:787–798. 2003.
22	Phan RT, Saito M, Basso K, et al: BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol. 6:1054–1060. 2005.
23	Polo JM, Dell’Oso T, Ranuncolo SM, et al: Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med. 10:1329–1335. 2004.
24	Pinto AE, André S, Silva G, et al: BCL-6 oncoprotein in breast cancer: loss of expression in disease progression. Pathobiology. 76:235–242. 2009.
25	Yamamoto S, Tomita Y, Hoshida Y, et al: Expression level of valosin-containing protein (p97) is correlated with progression and prognosis of non-small-cell lung carcinoma. Ann Surg Oncol. 11:697–704. 2004.
26	Yi P, Higa A, Taouji S, et al: Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death. Mol Cancer Ther. 11:2610–2620. 2012.
27	Yamamoto S, Tomita Y, Hoshida Y, et al: Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastriccarcinoma. J Clin Oncol. 21:2537–2544
28	Yamamoto S, Tomita Y, Hoshida Y, et al: Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis. Clin Cancer Res. 10:651–657. 2004.